Tackling the excesses of pharmaceutical marketing and promotion
BMJ
.
2024 May 21:385:e076797.
doi: 10.1136/bmj-2023-076797.
Authors
Ravi Gupta
1
2
,
Reshma Ramachandran
3
4
,
Joseph S Ross
3
4
5
6
Affiliations
1
Divison of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA ravigupta@jhmi.edu.
2
Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
3
Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), Yale School of Medicine, New Haven, CT, USA.
4
Section of General Internal Medicine and National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, USA.
5
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA.
6
Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA.
PMID:
38772671
DOI:
10.1136/bmj-2023-076797
No abstract available
Publication types
Editorial
MeSH terms
Advertising
Drug Industry*
Humans
Marketing*
United Kingdom